{"pmid":32444354,"title":"Test Agreement Between Roche Cobas 6800 and Cepheid GeneXpert Xpress SARS-CoV-2 Assays at High Cycle Threshold Ranges.","text":["Test Agreement Between Roche Cobas 6800 and Cepheid GeneXpert Xpress SARS-CoV-2 Assays at High Cycle Threshold Ranges.","The SARS-CoV-2 pandemic has changed the face of the globe and upended the daily lives of billions.....","J Clin Microbiol","Broder, Kari","Babiker, Ahmed","Myers, Charles","White, Terri","Jones, Heather","Cardella, John","Burd, Eileen M","Hill, Charles E","Kraft, Colleen S","32444354"],"abstract":["The SARS-CoV-2 pandemic has changed the face of the globe and upended the daily lives of billions....."],"journal":"J Clin Microbiol","authors":["Broder, Kari","Babiker, Ahmed","Myers, Charles","White, Terri","Jones, Heather","Cardella, John","Burd, Eileen M","Hill, Charles E","Kraft, Colleen S"],"date":"2020-05-24T11:00:00Z","year":2020,"_id":"32444354","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1128/JCM.01187-20","weight":0,"_version_":1667600475807023104,"score":9.490897,"similar":[{"pmid":32303565,"title":"The Detection of SARS-CoV-2 using the Cepheid Xpert Xpress SARS-CoV-2 and Roche cobas SARS-CoV-2 Assays.","text":["The Detection of SARS-CoV-2 using the Cepheid Xpert Xpress SARS-CoV-2 and Roche cobas SARS-CoV-2 Assays.","SARS-CoV-2, a novel coronavirus responsible for a December 2019 outbreak in Wuhan, China, causes a syndrome characterized by fever, cough, and dyspnea progressing to acute respiratory distress syndrome (1).....","J Clin Microbiol","Moran, Angelica","Beavis, Kathleen G","Matushek, Scott M","Ciaglia, Carol","Francois, Nina","Tesic, Vera","Love, Nedra","32303565"],"abstract":["SARS-CoV-2, a novel coronavirus responsible for a December 2019 outbreak in Wuhan, China, causes a syndrome characterized by fever, cough, and dyspnea progressing to acute respiratory distress syndrome (1)....."],"journal":"J Clin Microbiol","authors":["Moran, Angelica","Beavis, Kathleen G","Matushek, Scott M","Ciaglia, Carol","Francois, Nina","Tesic, Vera","Love, Nedra"],"date":"2020-04-19T11:00:00Z","year":2020,"_id":"32303565","source":"PubMed","week":"202016|Apr 13 - Apr 19","doi":"10.1128/JCM.00772-20","locations":["Wuhan","China"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Diagnosis"],"weight":1,"_version_":1666138491037155330,"score":114.91467},{"pmid":32405252,"pmcid":"PMC7217789","title":"Comparison of Cepheid Xpert Xpress and Abbott ID Now to Roche cobas for the Rapid Detection of SARS-CoV-2.","text":["Comparison of Cepheid Xpert Xpress and Abbott ID Now to Roche cobas for the Rapid Detection of SARS-CoV-2.","Background: The SARS-CoV-2 pandemic has created an urgent and unprecedented need for rapid large-scale diagnostic testing to inform timely patient management. However, robust data are lacking on the relative performance of available rapid molecular tests across a full range of viral concentrations. Objective: This study aimed to compare two recently-authorized rapid tests, Cepheid Xpert Xpress SARS-CoV-2 and Abbott ID Now SARS-CoV-2, to the Roche cobas SARS-CoV-2 assay for samples with low, medium, and high viral concentrations. Study design: A total of 113 nasopharyngeal swabs from remnant patient samples were tested, including 88 positives spanning the full range of observed Ct values on the cobas assay. Results: Compared to cobas, the overall positive agreement was 73.9% with ID Now and 98.9% with Xpert. Negative agreement was 100% and 92.0% for ID Now and Xpert, respectively. Both ID Now and Xpert showed 100% positive agreement for medium and high viral concentrations (Ct value <30). However, for Ct values >30, positive agreement was 34.3% for ID Now and 97.1% for Xpert. Conclusions: While Xpert showed high agreement with cobas across a wide range of viral concentrations, this study highlights an important limitation of ID Now for specimens collected in viral or universal transport media with low viral concentrations. Further studies are needed to evaluate the performance of ID Now for direct swabs.","J Clin Virol","Smithgall, Marie C","Scherberkova, Ioana","Whittier, Susan","Green, Daniel A","32405252"],"abstract":["Background: The SARS-CoV-2 pandemic has created an urgent and unprecedented need for rapid large-scale diagnostic testing to inform timely patient management. However, robust data are lacking on the relative performance of available rapid molecular tests across a full range of viral concentrations. Objective: This study aimed to compare two recently-authorized rapid tests, Cepheid Xpert Xpress SARS-CoV-2 and Abbott ID Now SARS-CoV-2, to the Roche cobas SARS-CoV-2 assay for samples with low, medium, and high viral concentrations. Study design: A total of 113 nasopharyngeal swabs from remnant patient samples were tested, including 88 positives spanning the full range of observed Ct values on the cobas assay. Results: Compared to cobas, the overall positive agreement was 73.9% with ID Now and 98.9% with Xpert. Negative agreement was 100% and 92.0% for ID Now and Xpert, respectively. Both ID Now and Xpert showed 100% positive agreement for medium and high viral concentrations (Ct value <30). However, for Ct values >30, positive agreement was 34.3% for ID Now and 97.1% for Xpert. Conclusions: While Xpert showed high agreement with cobas across a wide range of viral concentrations, this study highlights an important limitation of ID Now for specimens collected in viral or universal transport media with low viral concentrations. Further studies are needed to evaluate the performance of ID Now for direct swabs."],"journal":"J Clin Virol","authors":["Smithgall, Marie C","Scherberkova, Ioana","Whittier, Susan","Green, Daniel A"],"date":"2020-05-15T11:00:00Z","year":2020,"_id":"32405252","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.1016/j.jcv.2020.104428","keywords":["covid-19","molecular diagnostics","pcr","point of care","sars-cov-2"],"locations":["cobas","Xpert","Xpert","Xpert","Xpert","cobas"],"topics":["Diagnosis"],"weight":1,"_version_":1666802845576331264,"score":104.75511},{"pmid":32434706,"title":"Comparison of Cepheid Xpert Xpress and Abbott ID Now to Roche cobas for the Rapid Detection of SARS-CoV-2.","text":["Comparison of Cepheid Xpert Xpress and Abbott ID Now to Roche cobas for the Rapid Detection of SARS-CoV-2.","BACKGROUND: The SARS-CoV-2 pandemic has created an urgent and unprecedented need for rapid large-scale diagnostic testing to inform timely patient management. However, robust data are lacking on the relative performance of available rapid molecular tests across a full range of viral concentrations. OBJECTIVE: This study aimed to compare two recently-authorized rapid tests, Cepheid Xpert Xpress SARS-CoV-2 and Abbott ID Now SARS-CoV-2, to the Roche cobas SARS-CoV-2 assay for samples with low, medium, and high viral concentrations. STUDY DESIGN: A total of 113 nasopharyngeal swabs from remnant patient samples were tested, including 88 positives spanning the full range of observed Ct values on the cobas assay. RESULTS: Compared to cobas, the overall positive agreement was 73.9% with ID Now and 98.9% with Xpert. Negative agreement was 100% and 92.0% for ID Now and Xpert, respectively. Both ID Now and Xpert showed 100% positive agreement for medium and high viral concentrations (Ct value <30). However, for Ct values >30, positive agreement was 34.3% for ID Now and 97.1% for Xpert. CONCLUSIONS: While Xpert showed high agreement with cobas across a wide range of viral concentrations, this study highlights an important limitation of ID Now for specimens collected in viral or universal transport media with low viral concentrations. Further studies are needed to evaluate the performance of ID Now for direct swabs.","J Clin Virol","Smithgall, Marie C","Scherberkova, Ioana","Whittier, Susan","Green, Daniel A","32434706"],"abstract":["BACKGROUND: The SARS-CoV-2 pandemic has created an urgent and unprecedented need for rapid large-scale diagnostic testing to inform timely patient management. However, robust data are lacking on the relative performance of available rapid molecular tests across a full range of viral concentrations. OBJECTIVE: This study aimed to compare two recently-authorized rapid tests, Cepheid Xpert Xpress SARS-CoV-2 and Abbott ID Now SARS-CoV-2, to the Roche cobas SARS-CoV-2 assay for samples with low, medium, and high viral concentrations. STUDY DESIGN: A total of 113 nasopharyngeal swabs from remnant patient samples were tested, including 88 positives spanning the full range of observed Ct values on the cobas assay. RESULTS: Compared to cobas, the overall positive agreement was 73.9% with ID Now and 98.9% with Xpert. Negative agreement was 100% and 92.0% for ID Now and Xpert, respectively. Both ID Now and Xpert showed 100% positive agreement for medium and high viral concentrations (Ct value <30). However, for Ct values >30, positive agreement was 34.3% for ID Now and 97.1% for Xpert. CONCLUSIONS: While Xpert showed high agreement with cobas across a wide range of viral concentrations, this study highlights an important limitation of ID Now for specimens collected in viral or universal transport media with low viral concentrations. Further studies are needed to evaluate the performance of ID Now for direct swabs."],"journal":"J Clin Virol","authors":["Smithgall, Marie C","Scherberkova, Ioana","Whittier, Susan","Green, Daniel A"],"date":"2020-05-22T11:00:00Z","year":2020,"_id":"32434706","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1016/j.jcv.2020.104428","keywords":["covid-19","molecular diagnostics","pcr","point of care","sars-cov-2"],"locations":["cobas","Xpert","Xpert","Xpert","Xpert","cobas"],"topics":["Diagnosis"],"weight":1,"_version_":1667521393829347328,"score":104.75511},{"pmid":32383179,"title":"Comparison of SARS-CoV-2 Detection from Nasopharyngeal Swab Samples by the Roche cobas(R) 6800 SARS-CoV-2 Test and a Laboratory-Developed Real-Time RT-PCR test.","text":["Comparison of SARS-CoV-2 Detection from Nasopharyngeal Swab Samples by the Roche cobas(R) 6800 SARS-CoV-2 Test and a Laboratory-Developed Real-Time RT-PCR test.","The urgent need to implement and rapidly expand testing for Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) infection has led to development of multiple assays. How these tests perform relative to one another is poorly understood. We evaluated the concordance between the Roche Diagnostics cobas(R) 6800 SARS-CoV-2 Test and a laboratory- developed Real-Time RT-PCR test (LDT) based on a modified Centers for Disease Control and Prevention (CDC) protocol, for the detection of SARS-CoV-2 in samples submitted to the Clinical Laboratories of the Mount Sinai Health System. 1006 Nasopharyngeal swabs in universal transport medium from persons under investigation were tested for SARS-CoV-2 as part of routine clinical care using the cobas SARS-CoV2 test with subsequent evaluation by the LDT. Cycle threshold values were analyzed and interpreted as either positive ('Detected' or 'Presumptive Positive'), negative ('Not Detected'), inconclusive, or invalid. Statistical analysis was performed using GraphPad Prism 8. The cobas SARS-CoV2 test reported 706 positives and 300 negatives. The LDT reported 640 positives, 323 negatives, 34 inconclusive, and 9 invalids. When excluding inconclusive and invalid results, the overall percent agreement between the two platforms was 95.8%. Cohen's kappa coefficient (kappa) was 0.904 (95 % CI 0.875-0.933), suggesting almost perfect agreement between both platforms. An overall discordance rate of 4.2% between the two systems may reflect differences in primer sequences, assay limit of detection, or other factors, highlighting the importance of comparing the performance of different testing platforms. This article is protected by copyright. All rights reserved.","J Med Virol","Pujadas, Elisabet","Ibeh, Nnaemeka","Hernandez, Matthew M","Waluszko, Aneta","Sidorenko, Tatyana","Flores, Vanessa","Shiffrin, Biana","Chiu, Numthip","Young-Francois, Alicia","Nowak, Michael D","Paniz-Mondolfi, Alberto E","Sordillo, Emilia M","Cordon-Cardo, Carlos","Houldsworth, Jane","Gitman, Melissa R","32383179"],"abstract":["The urgent need to implement and rapidly expand testing for Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) infection has led to development of multiple assays. How these tests perform relative to one another is poorly understood. We evaluated the concordance between the Roche Diagnostics cobas(R) 6800 SARS-CoV-2 Test and a laboratory- developed Real-Time RT-PCR test (LDT) based on a modified Centers for Disease Control and Prevention (CDC) protocol, for the detection of SARS-CoV-2 in samples submitted to the Clinical Laboratories of the Mount Sinai Health System. 1006 Nasopharyngeal swabs in universal transport medium from persons under investigation were tested for SARS-CoV-2 as part of routine clinical care using the cobas SARS-CoV2 test with subsequent evaluation by the LDT. Cycle threshold values were analyzed and interpreted as either positive ('Detected' or 'Presumptive Positive'), negative ('Not Detected'), inconclusive, or invalid. Statistical analysis was performed using GraphPad Prism 8. The cobas SARS-CoV2 test reported 706 positives and 300 negatives. The LDT reported 640 positives, 323 negatives, 34 inconclusive, and 9 invalids. When excluding inconclusive and invalid results, the overall percent agreement between the two platforms was 95.8%. Cohen's kappa coefficient (kappa) was 0.904 (95 % CI 0.875-0.933), suggesting almost perfect agreement between both platforms. An overall discordance rate of 4.2% between the two systems may reflect differences in primer sequences, assay limit of detection, or other factors, highlighting the importance of comparing the performance of different testing platforms. This article is protected by copyright. All rights reserved."],"journal":"J Med Virol","authors":["Pujadas, Elisabet","Ibeh, Nnaemeka","Hernandez, Matthew M","Waluszko, Aneta","Sidorenko, Tatyana","Flores, Vanessa","Shiffrin, Biana","Chiu, Numthip","Young-Francois, Alicia","Nowak, Michael D","Paniz-Mondolfi, Alberto E","Sordillo, Emilia M","Cordon-Cardo, Carlos","Houldsworth, Jane","Gitman, Melissa R"],"date":"2020-05-09T11:00:00Z","year":2020,"_id":"32383179","source":"PubMed","week":"202019|May 04 - May 10","doi":"10.1002/jmv.25988","keywords":["rna extraction","sars","coronavirus"],"locations":["kappa"],"topics":["Diagnosis"],"weight":1,"_version_":1666419683348185088,"score":76.65225},{"pmid":32366669,"title":"Multicenter Evaluation of the Cepheid Xpert Xpress SARS-CoV-2 Test.","text":["Multicenter Evaluation of the Cepheid Xpert Xpress SARS-CoV-2 Test.","Background. Nucleic acid amplification tests (NAATs) are the primary means of identifying acute infections caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Accurate and fast test results may permit more efficient use of protective and isolation resources and allow for rapid therapeutic interventions.Methods. We evaluated the analytical and clinical performance characteristics of the Xpert(R) Xpress SARS-CoV-2 (Xpert) test, a rapid, automated molecular test for SARS-CoV-2. Analytical sensitivity and specificity/interference were assessed with infectious SARS-CoV-2, other infectious coronavirus species including SARS-CoV, and 85 nasopharyngeal swab specimens positive for other respiratory viruses including endemic human coronaviruses (hCoVs). Clinical performance was assessed using 483 remnant upper and lower respiratory specimens previously analyzed by standard of care (SOC) NAATs.Results. The limit of detection of the Xpert test was 0.01 plaque forming units (PFU)/mL. Other hCoVs, including Middle East Respiratory Syndrome coronavirus, were not detected by the Xpert test. SARS-CoV, a closely related species in the Sarbecovirus subgenus, was detected by a broad-range target (E) but was distinguished from SARS-CoV-2 (SARS-CoV-2-specific N2 target). Compared to SOC NAATs, the positive agreement of the Xpert test was 219/220 (99.5%) and the negative agreement was 250/261 (95.8%). A third tie-breaker NAAT resolved all but three of the discordant results in favor the Xpert test.Conclusions. The Xpert test provided sensitive and accurate detection of SARS-CoV-2 in a variety of upper and lower respiratory tract specimens. The high sensitivity and fast time to results of approximately 45 minutes may impact patient management.","J Clin Microbiol","Loeffelholz, Michael J","Alland, David","Butler-Wu, Susan M","Pandey, Utsav","Perno, Carlo Frederico","Nava, Alice","Carroll, Karen C","Mostafa, Heba","Davies, Emma","McEwan, Ashley","Rakeman, Jennifer L","Fowler, Randal C","Pawlotsky, Jean-Michel","Fourati, Slim","Banik, Sukalyani","Banada, Padmapriya P","Swaminathan, Shobha","Chakravorty, Soumitesh","Kwiatkowski, Robert W","Chu, Victor C","Kop, JoAnn","Gaur, Rajiv","Sin, Mandy L Y","Nguyen, Duy","Singh, Simranjit","Zhang, Na","Persing, David H","32366669"],"abstract":["Background. Nucleic acid amplification tests (NAATs) are the primary means of identifying acute infections caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Accurate and fast test results may permit more efficient use of protective and isolation resources and allow for rapid therapeutic interventions.Methods. We evaluated the analytical and clinical performance characteristics of the Xpert(R) Xpress SARS-CoV-2 (Xpert) test, a rapid, automated molecular test for SARS-CoV-2. Analytical sensitivity and specificity/interference were assessed with infectious SARS-CoV-2, other infectious coronavirus species including SARS-CoV, and 85 nasopharyngeal swab specimens positive for other respiratory viruses including endemic human coronaviruses (hCoVs). Clinical performance was assessed using 483 remnant upper and lower respiratory specimens previously analyzed by standard of care (SOC) NAATs.Results. The limit of detection of the Xpert test was 0.01 plaque forming units (PFU)/mL. Other hCoVs, including Middle East Respiratory Syndrome coronavirus, were not detected by the Xpert test. SARS-CoV, a closely related species in the Sarbecovirus subgenus, was detected by a broad-range target (E) but was distinguished from SARS-CoV-2 (SARS-CoV-2-specific N2 target). Compared to SOC NAATs, the positive agreement of the Xpert test was 219/220 (99.5%) and the negative agreement was 250/261 (95.8%). A third tie-breaker NAAT resolved all but three of the discordant results in favor the Xpert test.Conclusions. The Xpert test provided sensitive and accurate detection of SARS-CoV-2 in a variety of upper and lower respiratory tract specimens. The high sensitivity and fast time to results of approximately 45 minutes may impact patient management."],"journal":"J Clin Microbiol","authors":["Loeffelholz, Michael J","Alland, David","Butler-Wu, Susan M","Pandey, Utsav","Perno, Carlo Frederico","Nava, Alice","Carroll, Karen C","Mostafa, Heba","Davies, Emma","McEwan, Ashley","Rakeman, Jennifer L","Fowler, Randal C","Pawlotsky, Jean-Michel","Fourati, Slim","Banik, Sukalyani","Banada, Padmapriya P","Swaminathan, Shobha","Chakravorty, Soumitesh","Kwiatkowski, Robert W","Chu, Victor C","Kop, JoAnn","Gaur, Rajiv","Sin, Mandy L Y","Nguyen, Duy","Singh, Simranjit","Zhang, Na","Persing, David H"],"date":"2020-05-06T11:00:00Z","year":2020,"_id":"32366669","source":"PubMed","week":"202019|May 04 - May 10","doi":"10.1128/JCM.00926-20","locations":["Xpert","Xpert","Xpert","Sarbecovirus","Xpert","Xpert","Xpert"],"topics":["Diagnosis"],"weight":1,"_version_":1666138496261160961,"score":72.56501}]}